Slides
Page 1
Puma Biotechnology Earnings Call Commercial Update February 26, 2026
Page 2
This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on our current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, any adverse impact on our business or the global economy and financial markets, generally, from the global COVID-19 pandemic, and the risk factors disclosed in our periodic and current reports filed with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent filings. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We assume no obligation to update these forward-looking statements except as required by law. Forward-Looking Safe-Harbor Statement
Page 3
3 Copyright 2026 Puma Biotechnology Patients Sites of Care Academic Hospitals Community Hospitals Physician Practices Others (VA, DOD) Hub Services Specialty Pharmacy Network (SP) Specialty Distributor Network (SD) Acaria Health Accredo CVS ONCO360 Optum / Diplomat Biologics Cardinal Health McKesson ASD / Oncology Supply DMS Pharmaceutical Group Inc. Puma’s Pharmacy and Distributor Network Bio Care
Page 4
4 Copyright 2026 Puma Biotechnology 54.4 59.9 Q4'24 Q4'25 Net Revenue (in $MM) ~10% increase in Q4’25 compared to Q4’24 ~15% increase in Q4’25 compared to Q3’25 Q3’25 Q4’25 $3.1 mil $5.7 mil Inventory Change ($) Inventory Change ($) Q4’24 Q4’25 $3.7 mil $5.7 mil $59.9 Million Net NERLYNX Revenue in Q4’25 51.9 59.9 Q3'25 Q4'25 Net Revenue (in $MM)
Page 5
5 Copyright 2026 Puma Biotechnology 2,964 3,298 Q4'24 Q4'25 Bottles ~11% increase in Q4’25 compared to Q4’24 ~12% increase in Q4’25 compared to Q3’25 Q4’24 Q4’25 205 343 Q3’25 Q4’25 182 343 Inventory Change Bottles Inventory Change Bottles 3,298 Ex-Factory Bottles Were Sold in Q4’25 2,949 3,298 Q3'25 Q4'25 Bottles
Page 6
6 Copyright 2026 Puma Biotechnology *Reduced dose defined as fewer than 6 pills per day 12% 11% 19% 28% 30% 31% 33% 42% 38% 36% 55% 59% 62% 65% 68% 64% 64% 70% 71% 76% 67% 66% 65% 74% 72% 71% 77% 75% % of Patients Starting at Reduced Dose ~75% of Patients in Q4’25 Started at a Reduced Dose*
Page 7
7 Copyright 2026 Puma Biotechnology Rest of World Partnerships – Timelines Region Partner Regulatory Approvals Commercial Launches Australia / SE Asia • 2019 – Ext. Adj. in Australia, Singapore • 2020 – Ext. Adj. in Brunei, Malaysia, New Zealand • 2022 – Ext. Adj. in the Philippines; mBC in Singapore • 2023 – mBC in Malaysia • 2024 – Ext. Adj. and mBC in Thailand • 2020 – Singapore • 2021 – Malaysia, Brunei, New Zealand • Q1 2026 – Thailand Israel • 2020 – Approved in Ext. Adj. and mBC • 2020 – Launched Canada • 2019 – Ext. Adj. approved • 2021 – mBC approved • 2020 – Launched Latin America • 2019 – Ext Adj in Argentina • 2020 – Ext. Adj in Chile, Ecuador; mBC in Argentina • 2021 – Ext Adj. and mBC in Peru; mBC in Chile; Ext. Adj. in Brazil • 2022 – Ext. Adj. in Mexico; mBC in Ecuador • 2023 – mBC in Colombia and Mexico • 2024 – mBC in Brazil • 2020 – Argentina • 2021 – Chile and Peru • 2022 – Brazil • 2023 – Mexico and Colombia Europe Greater China Middle East North and West Africa South Africa Turkey • 2019 – Ext. Adj. EMA and Hong Kong • 2020 – Ext. Adj. in China, Taiwan • 2021 – mBC in Taiwan • 2023 – Ext. Adj. in Morocco, South Africa, and UAE • 2024 – Ext. Adj. in Syria, Saudi Arabia, Algeria, Turkey • Q3 2025 – Ext. Adj. in Lebanon • 2019 – Germany, UK, Austria • 2020 – Sweden, Finland, Scotland, Switzerland, Denmark, HK • 2021 – China, Taiwan, Greece, Czech Republic, Luxembourg • 2022 – Ireland and Spain • 2023 – Slovakia • 2024 – Morocco, South Africa, UAE, Turkey, Saudi Arabia • Q1 2025 – Libya Q4 2025 – Algeria South Korea • 2021 – Ext. Adj. in S. Korea • 2022 – Launched Russia/CIS • Distribution agreement executed
Page 8
Puma Biotechnology Earnings Call Commercial Update February 26, 2026